SURVYR

ALKS

Alkermes plc
$43.82
−$0.36 (0.81%)Oct 23 close
Health CareS&P 600 CompareTechnicals
1M3M6M1Y2Y
-13%+10%+33%+56%+79%Oct 2025Oct 2026Apr 202652w high $55.6752w low $27.00
ALKSSPY
Wall St. Highest PT $83.00 (+89.4%) Wall St. Avg PT $56.21 (+28.3%)
$27$42$56$71$85POC $34Hi $83Avg $56
Underwater Drawdown %Max DD -29.2%Current -20.6%
0.0%-29.2%
Relative Strength vs SPY+25.9% vs SPYOutperforming
+77%0%-77%
1W
+$2.60 (6.31%)
1M
+$1.69 (4.01%)
3M
−$9.07 (17.15%)
6M
+$10.51 (31.55%)
YTD
+$15.84 (56.61%)
1Y
+$13.78 (45.87%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
19 analysts · mean score 1.70
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$43.82
Average target$56.21
+$12.39 (+28.3%) upsideaverage target vs current price
CurrentAverageMedian
Low$38.00
Median$56.21
High$83.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-09-22 · RBC Capital reiterated Outperform on ALKS
Reiterated
2026-09-22 · Baird reiterated Outperform on ALKS
Reiterated
2026-09-21 · Needham reiterated Buy on ALKS
Reiterated
2026-07-29 · JP Morgan reiterated Neutral on ALKS
Reiterated
2026-07-29 · Baird reiterated Outperform on ALKS
Reiterated
2026-07-28 · Piper Sandler reiterated Overweight on ALKS
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$7.4B
P/E (last 12 months)115.3
P/E (next 12 months, estimated)24.2
52-week range$27.00 – $55.67
Revenue growth (latest quarter vs a year ago)+27.0%
Dividend yieldNo dividend
Analyst consensusBuy (19)
Average analyst price target$56.21 (+28%)

What they do

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I.

Healthcare · Drug Manufacturers - Specialty & Generic
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
67th percentile in sector
B
12-1 return: +32.0%
Percentile within its GICS sector across the S&P 1500.
Growth
87th percentile in sector
A-
Revenue growth (YoY): +27.0%
Percentile within its GICS sector across the S&P 1500.
Value
25th percentile in sector
D+
Forward E/P: 4.4% · EBITDA/EV: 3.6%
Percentile within its GICS sector across the S&P 1500.
Profitability
35th percentile in sector
C-
Profit margin: +4.0% · Return on equity: +3.9%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

ALKS earningsNext report in 7 days
Next report · quarter Sep 2026
Tue Nov 3, 2026Before the open
EPS consensus$0.25 range -$0.04–$0.51
Revenue consensus$465.1M 18 analysts
Last 4 quarters · EPS vs estimate
Jul 28, 2026$0.70est $0.29+141.3%Above estimates
May 5, 2026$0.38est -$0.04+1053.0%Above estimates
Feb 25, 2026$0.48est $0.45+7.7%Above estimates
Oct 28, 2025$0.65est $0.39+68.5%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-23 12:54:45 ET
24-1025-0225-0525-0725-1026-0226-0526-07-0.041.05
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-03-31$392.9M+28.2%
2025-12-31$384.5M–
2025-09-30$394.2M–
2025-06-30$390.7M–
2025-03-31$306.5M–

News & catalysts

More news
Alkermes to Report Third Quarter Financial Results on November 3, 2026
Business Wire · Oct 20
Earnings Preview: Alkermes (ALKS) Q3 Earnings Expected to Decline
Zacks · Oct 20
What First Trust NYSE Arca Biotech (FBT) Bought: Tarsus Leads on Oct. 16
GuruFocus.com · Oct 20
Workday downgraded, Fox Corp. upgraded: Wall Street's top analyst calls
The Fly · Oct 16
HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth?
Zacks · Oct 16
Rating changes
Reiterated
2026-09-22 · RBC Capital reiterated Outperform on ALKS
Reiterated
2026-09-22 · Baird reiterated Outperform on ALKS
Reiterated
2026-09-21 · Needham reiterated Buy on ALKS
Reiterated
2026-07-29 · JP Morgan reiterated Neutral on ALKS
Reiterated
2026-07-29 · Baird reiterated Outperform on ALKS
Reiterated
2026-07-28 · Piper Sandler reiterated Overweight on ALKS

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-23 12:54:45 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026